Novel water-soluble gelatin-based platinum nanoparticles for targeted cancer therapy with enhanced cytotoxicity

The development of effective and targeted cancer therapies remains a significant challenge. Platinum-based drugs are widely used but often suffer from limitations such as systemic toxicity and resistance. This study presents a novel approach to address these limitations by developing water-soluble gelatin-based platinum nanoparticles (PtNPs) for enhanced cancer therapy. The incorporation of gelatin and curcumin into these nanoparticles offers potential advantages in terms of biocompatibility, targeted delivery, and synergistic therapeutic effects. The PtNPs were conveniently synthesized using a nanosuspension technique, offering a potentially scalable and straightforward method for nanoparticle production. The synthesized PtNPs were thoroughly characterized using various techniques. The investigation assessed the cytotoxic properties of the PtNPs in MCF-7 (breast cancer) and HepG2 (liver cancer) cell lines. The average size of PtNPs was found to vary around 120-200 nm. The density of platinum metal was supported by EDS and metal mapping analysis. The IC50 values of PtNPs in MCF-7 and HepG2 cancer cell lines were found to be 6.450 and 7.992 mu L/mL, respectively. The incorporation of gelatin and curcumin into platinum nanoparticles represents a unique and innovative strategy for enhancing nanoparticle biocompatibility, targeting, and therapeutic efficacy.